Compare PAYC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYC | BMRN |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 12.3B |
| IPO Year | 2014 | 1999 |
| Metric | PAYC | BMRN |
|---|---|---|
| Price | $248.30 | $58.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 28 |
| Target Price | ★ $271.00 | $90.19 |
| AVG Volume (30 Days) | 659.3K | ★ 2.2M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 8.40 | 0.14 |
| Revenue | $433,047,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $7.98 | $20.05 |
| Revenue Next Year | $7.59 | $14.91 |
| P/E Ratio | ★ $30.35 | $414.29 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $104.90 | $49.26 |
| 52 Week High | $275.22 | $70.98 |
| Indicator | PAYC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 53.64 |
| Support Level | $213.03 | $58.03 |
| Resistance Level | $274.15 | $58.39 |
| Average True Range (ATR) | 9.75 | 1.86 |
| MACD | -1.85 | 0.33 |
| Stochastic Oscillator | 43.94 | 81.89 |
Paycom is a cloud-based human capital management provider offering payroll, compliance, and human resources management solutions. The firm's solutions are available on a unified, modular platform, and customers are billed for access on a subscription basis. Paycom's customer base skews toward the midmarket and is primarily based in North America. As of 2025, the firm manages records for 7.4 million employees across more than 20,000 clients on a parent-company-group basis.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.